Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
JCE Stock Summary
Top 10 Correlated ETFs
JCE
In the News

Weekly Closed-End Fund Roundup: February 19, 2023
0 out of 22 closed-end fund sectors positive on price and 3 out of 22 sectors positive on NAV last week. KIO rights offering results.

JCE: Portfolio Reconstruction Should Support Continued High Yield And Return
Nuveen Core Equity Alpha Fund pays a quarterly dividend, generating strong yield. This yield is likely sustainable over the long term, due to its current investment strategy. JCE is a closed-end fund with a diversified equity portfolio and offers investors an attractive option to invest in dividend-paying large-cap equities in the U.S. market.

Weekly Closed-End Fund Roundup: January 8, 2023
21 out of 22 CEF sectors were positive on price and 20 out of 22 sectors were positive on NAV last week. MLPs are the most discounted CEF sector.

Weekly Closed-End Fund Roundup: VFL Tender Results (December 18, 2022)
2 out of 23 CEF sectors were positive on price and 2 out of 23 sectors were positive on NAV last week. VFL offers tender results.

Weekly Closed-End Fund Roundup: DEX Will Merge With AGD, Tender Next January (December 11, 2022)
2 out of 23 CEF sectors positive on price and 4 out of 23 sectors positive on NAV last week. DEX will merge with AGD.

Weekly Closed-End Fund Roundup: Tortoise Tender Results, NCZ Resumes Distributions (November 6, 2022)
12 out of 23 CEF sectors positive on price and 6 out of 23 sectors positive on NAV last week. Tortoise offer tender results.

Weekly Closed-End Fund Roundup: Tortoise Tender Offers Expiring (October 23, 2022)
16 out of 23 CEF sectors positive on price and 12 out of 23 sectors positive on NAV last week. Watch for overvalued CEFs as market volatility rises.

JCE: A "Hold" But Some Potential Alternatives
Since our previous update, JCE remains at a premium - even ticking up a bit. Some alternatives could exist with better valuations, such as FFA and IGA.

Weekly Closed-End Fund Roundup: BlackRock CEFs Repurchasing Shares (October 16, 2022)
0 out of 23 CEF sectors are positive on price and 0 out of 23 sectors are positive on NAV over the last week. BlackRock CEFs are repurchasing their shares.

JCE: Some Potential, But Looking For A Discount
JCE has declined along with the rest of the markets this year; it stubbornly hangs onto its premium valuation. The fund has generated alpha this year on a NAV basis, as its name implies, but it has only been very minimal.
JCE Financial details
JCE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | -0.95 | 3.37 | 1.14 | 3.97 | 0 | |
Net income per share | -0.97 | 3.36 | 1.1 | 3.96 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0.01 | 0 | 0 | 0 | |
Book value per share | 12.75 | 15.07 | 15.25 | 17.37 | 0 | |
Tangible book value per share | 12.75 | 15.17 | 15.38 | 17.41 | 0 | |
Share holders equity per share | 12.75 | 15.07 | 15.25 | 17.37 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 191.89M | 233.79M | 224.91M | 297.49M | 0 | |
Enterprise value | 191.88M | 233.71M | 224.88M | 297.49M | -6.85K | |
P/E ratio | -12.4 | 4.35 | 12.79 | 4.69 | 0 | |
Price to sales ratio | -12.6 | 4.33 | 12.38 | 4.68 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0.94 | 0.97 | 0.92 | 1.07 | 0 | |
PTB ratio | 0.94 | 0.97 | 0.92 | 1.07 | 0 | |
EV to sales | -12.6 | 4.33 | 12.38 | 4.68 | 0 | |
Enterprise value over EBITDA | -12.4 | 4.35 | 12.79 | 4.69 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | -0.08 | 0.23 | 0.08 | 0.21 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 0 | 7.04 | 0 | 0 | 0 | |
Interest coverage | 0 | 0 | 0 | 94.92K | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | -0.02 | 0 | 0.04 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 16.68 | 33.76 | 19.43 | 39.33 | 0 | |
ROIC | -0.08 | 0.22 | 0.07 | 0.23 | -0.25 | |
Return on tangible assets | -0.08 | 0.22 | 0.07 | 0.23 | -0.24 | |
Graham Net | -0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Working capital | 260.91K | 410.43K | 199.06K | 178K | 438.23K | |
Tangible asset value | 203.32M | 242.51M | 245.8M | 278.74M | 194.54M | |
Net current asset value | -269.44K | 410.43K | 199.06K | 178K | 438.23K | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 1.15M | 325K | 278.16K | 169.78K | 302.5K | |
Average payables | 280.12K | 33.99K | 33.99K | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | -6.22 | 2.64 | 3.33 | 1 | -3.33 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | -58.67 | 138.22 | 109.47 | 366.47 | -109.46 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.08 | 0.22 | 0.07 | 0.23 | -0.25 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | -33.11K | 0 | -4.39K | -6.85K | -6.85K | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 0 | 0.02 | 0 | 0.02 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 199.06K | -4.66M | 178K | -6.11M | 438.23K | |
Tangible asset value | 243.79M | 270.42M | 278.04M | 217.01M | 194.54M | |
Net current asset value | -1.81M | -5.97M | -521.91K | -6.76M | 438.23K | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 1.98M | 140.98K | 144.81K | 132.81K | 261.7K | |
Average payables | 1.76M | 2.39M | 2.39M | 3.1M | 3.1M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
JCE Frequently Asked Questions
What is Nuveen Core Equity Alpha Fund stock symbol ?
Nuveen Core Equity Alpha Fund is a US stock , located in Chicago of Il and trading under the symbol JCE
What is Nuveen Core Equity Alpha Fund stock quote today ?
Nuveen Core Equity Alpha Fund stock price is $12.2316 today.
Is Nuveen Core Equity Alpha Fund stock public?
Yes, Nuveen Core Equity Alpha Fund is a publicly traded company.